In vitro immunoresponsiveness in recipients of cadaveric renal allografts during ATG therapy.
Proc Eur Dial Transplant Assoc
; 18: 481-5, 1981.
Article
en En
| MEDLINE
| ID: mdl-7036170
ABSTRACT
Anti-human-T-cell-globulin (ATG-Fresenius) was given prophylactically in a fixed dose of 2mg per kg bodyweight to 32 renal allograft recipients in addition to a conventional immunosuppressive regimen, over a period of 20 days. ATG therapy resulted in a significant decrease of circulating T-lymphocytes, whereas B-lymphocytes remained unaffected. The mitogen reactivity during therapy paralleled the T-lymphocyte profile with a maximum decrease on day 8. With in vitro testing of ATG immunoresponsiveness it could be demonstrated that patients with rejection episodes after transplantation reacted differently from patients without signs of rejection. Actuarial patient and graft survival was about 5% higher in the ATG treated group of patients than in retrospective controls.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trasplante de Riñón
/
Supervivencia de Injerto
/
Inmunosupresores
/
Suero Antilinfocítico
Límite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Humans
/
Middle aged
Idioma:
En
Revista:
Proc Eur Dial Transplant Assoc
Año:
1981
Tipo del documento:
Article